Preclinical evaluation of novel synthesised nanoparticles based on tyrosine poly(ester amide) for improved targeted pulmonary delivery.
Dry powder inhaler
Fluticasone propionate
Interfacial polycondensation
Salmeterol xinafoate
Tyrosine-based poly (ester amide)
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
29 04 2024
29 04 2024
Historique:
received:
10
02
2024
accepted:
12
04
2024
medline:
30
4
2024
pubmed:
30
4
2024
entrez:
29
4
2024
Statut:
epublish
Résumé
Fixed dose combinations (FDCs) incorporating two or three medicines in a single inhaler have been created to enhance patient compliance and hence clinical outcomes. However, the development of dry powder inhalers (DPIs), particularly for FDCs, faces challenges pertinent to formulation uniformity and reproducibility. Therefore, this project aimed to employ nanotechnology to develop a FDC of DPIs for market-leading medicines-fluticasone propionate (FP) and salmeterol xinafoate (SAL)-for asthma management. Nanoaggregates were prepared using a novel biocompatible and biodegradable poly(ester amide) based on the amino acid tyrosine, utilising a one-step interfacial polymerisation process. The produced tyrosine poly (ester amide) drug-loaded nanoparticles were evaluated for content uniformity, PSA, FTIR, TEM, DSC, XRD and aerodynamic performance (in vitro and in vivo). The optimised formulation demonstrated high entrapment efficiency- > 90%. The aerodynamic performance in terms of the emitted dose, fine particle fraction and respirable dose was superior to the carrier-based marketed product. In-vivo studies showed that FP (above the marketed formulation) and SAL reached the lungs of mice in a reproducible manner. These results highlight the superiority of novel FDC FP/SAL nanoparticles prepared via a one-step process, which can be used as a cost-effective and efficient method to alleviate the burden of asthma.
Identifiants
pubmed: 38684750
doi: 10.1038/s41598-024-59588-1
pii: 10.1038/s41598-024-59588-1
doi:
Substances chimiques
Tyrosine
42HK56048U
Polyesters
0
Fluticasone
CUT2W21N7U
Salmeterol Xinafoate
6EW8Q962A5
Drug Carriers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
9845Subventions
Organisme : Jordan Isra University
ID : (RC: 8-43/2020-2021 on 19-8-2021)
Informations de copyright
© 2024. The Author(s).
Références
Annu Rev Chem Biomol Eng. 2010;1:149-73
pubmed: 22432577
Nat Rev Drug Discov. 2021 Feb;20(2):101-124
pubmed: 33277608
Acta Pharmacol Sin. 2017 Jun;38(6):782-797
pubmed: 28504252
Polymers (Basel). 2022 Mar 08;14(6):
pubmed: 35335412
Membranes (Basel). 2021 May 07;11(5):
pubmed: 34067194
Adv Drug Deliv Rev. 2023 Nov;202:115111
pubmed: 37820982
J Pharm Sci. 2010 May;99(5):2343-56
pubmed: 19967777
Int J Mol Sci. 2014 Apr 08;15(4):5852-73
pubmed: 24717409
Int J Pharm. 2020 Jul 30;585:119516
pubmed: 32525079
Molecules. 2020 Aug 26;25(17):
pubmed: 32859128
Biomater Res. 2020 Jun 06;24:12
pubmed: 32537239
Environ Health Perspect. 2007 May;115(5):728-33
pubmed: 17520060
Pharm Dev Technol. 2022 Dec;27(10):1057-1068
pubmed: 36416448
Molecules. 2020 Aug 15;25(16):
pubmed: 32824172
Adv Drug Deliv Rev. 2022 Jun;185:114309
pubmed: 35469997
Pharmaceuticals (Basel). 2022 Mar 08;15(3):
pubmed: 35337119
Int J Biol Macromol. 2021 Oct 1;188:542-567
pubmed: 34384802
Chem Rev. 2016 Feb 24;116(4):2602-63
pubmed: 26854975
Int J Nanomedicine. 2009;4:299-319
pubmed: 20054434
Int J Nanomedicine. 2019 Nov 13;14:8875-8889
pubmed: 32009785
Adv Drug Deliv Rev. 2013 Nov;65(13-14):1816-27
pubmed: 23932923
Nat Rev Mater. 2021 Apr;6(4):351-370
pubmed: 34950512
Pharmaceutics. 2024 Jan 24;16(2):
pubmed: 38399222
J Control Release. 2023 Mar;355:292-311
pubmed: 36739908
Chem Pharm Bull (Tokyo). 2019;67(12):1328-1336
pubmed: 31787659
Curr Opin Chem Biol. 2001 Aug;5(4):447-51
pubmed: 11470609